Further understanding of the mechanisms governing DKK1's immune modulatory and tumour‐promoting activity in iCCA is required to provide a rationale for patient stratification or therapy combinations in which DKK1 inhibition can be levied in the most effective way. The gene discussed is DKK1; the disease is neoplasm.